We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
HUTCHMEDA sharper focus on the path to profitability
HUTCHMEDFruquintinib should continue to bear fruit
Arecor TherapeuticsSpecialty Hospital products formulation collaboration
Futura MedicalOn the cusp of MED3000 commercialisation
ScancellFY22 results highlight clinical and corporate progress
Allergy TherapeuticsManufacturing pause takes it toll on revenues
ScancellOptimum partner secured for first antibody deal
AvactaDiagnostics M&A-led growth strategy is ready to Launch
Arecor TherapeuticsAT247 Phase I pump data confirms promising profile
Redx PharmaNew data draws attention to promising fibrosis assets